Diabetes

Ägypten hat im Rahmen seines Programms „100 Million Healthy Lives“ eine präsidiale Initiative zur Unterstützung von Kindern mit Typ-1-Diabetes ins Leben gerufen, bei der Technologien zur kontinuierlichen Glukosemessung eingesetzt werden.

18. Juni 2026 Von KI berichtet

The FDA has cleared Dexcom’s Stelo Glucose Biosensor System for use by people ages 2 and older who do not use insulin. The decision, announced June 12, makes Stelo the first over-the-counter continuous glucose monitor approved for children.

A randomized trial showed that adults with prediabetes experienced no negative changes in blood sugar control or insulin function after eating beef daily for a month. The findings matched results from a poultry-based diet.

21. Mai 2026 Von KI berichtet Fakten geprüft

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Researchers in Sweden have created insulin-producing cells from human stem cells that reversed diabetes symptoms when transplanted into mice. The cells matured after placement in the eye and maintained glucose regulation for months. The work was published in Stem Cell Reports.

4. Mai 2026 Von KI berichtet

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.